Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – Read More
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and Read More
Miami Breast 2020 FLEX Trials in Progress
AUTHORS: Robert Maganini, Pond Kelemen, Jennifer A. Crozier, Gordan Srkalovic, Read More
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
PUBLICATION: Soliman et al. BMC Cancer (2020) 20:81 AUTHORS: Hatem Read More
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Read More
Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Read More
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse
PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Read More
PROMIS study findings presented at SABCS 2019
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Read More
SABCS 2019: Cyclin E Expression
AUTHORS: Lorenza Mittempergher, Joseph McKelley, Rajith Bhaskaran, Sahra Uygun, René Read More
SABCS 2019: FLEX Trials in Progress
AUTHORS: Jennifer Crozier, Gordan Srkalovic, Adam Brufsky, Mehran Habibi, Pat Read More